Brief: Tempest Releases New Data Demonstrating Superiority Of TPST-1120 Arm Across Multiple Study Endpoints In Randomized First-Line Hcc Study

Tempest Therapeutics

11/10/2023 13:09

Oct 11 (Reuters) - Tempest Therapeutics Inc  TPST.O :
    * TEMPEST RELEASES NEW DATA DEMONSTRATING SUPERIORITY OF
TPST-1120
ARM ACROSS MULTIPLE STUDY ENDPOINTS IN RANDOMIZED FIRST-LINE HCC
STUDY
    * TEMPEST THERAPEUTICS INC - ENROLLMENT BEGAN IN FALL OF
2021 AND
CUTOFF DATE FOR THESE DATA WAS APRIL 20, 2023
    * TEMPEST - RANDOMIZED ARMS WERE GENERALLY WELL BALANCED AT
BASELINE SECONDARY ENDPOINTS INCLUDE DOR, PFS, OS, WHICH ARE NOT
FULLY MATURE AS OF DATA CUT
    * TEMPEST THERAPEUTICS INC - IN ROCHE'S IMBRAVE150 PHASE 3
TRIAL,
CONFIRMED ORR BENEFIT CORRELATED WITH OVERALL SURVIVAL (OS)
BENEFIT

Source text for Eikon:  ID:nGNX4nNbx0 
Further company coverage:  TPST.O 

 ((Reuters.Briefs@thomsonreuters.com))